Other lymphocyte receptors on B cells and immune cells

Other lymphocyte receptors on B cells and immune cells is a broad, non-specific category used to group various cell surface proteins that facilitate immune signaling and cellular interactions. This classification encompasses a wide range of molecules, including B-cell-specific markers like CD19, CD20, and CD22, as well as co-stimulatory and inhibitory receptors found on various leukocyte subsets (Janeway et al., Immunobiology, 2001). These receptors are essential for the development and regulation of the adaptive immune response, serving as the primary interface for antigen recognition and subsequent intracellular signaling (Nature Reviews Immunology, 2010). In clinical practice, many of these receptors are targeted by monoclonal antibodies and other immunotherapies to treat hematologic malignancies and autoimmune disorders (NCBI, 2023). Because this is a collective term rather than a single molecular entity, it does not have a uniform mechanism of action or safety profile. Instead, the pharmacological effects and clinical outcomes are highly dependent on the specific receptor being targeted within this broad group. Common therapeutic challenges associated with targeting these receptors include systemic immunosuppression and the risk of cytokine release syndrome (StatPearls, 2023).

Other names

Lymphocyte surface receptorsB-cell surface antigensImmune cell surface markersLeukocyte differentiation antigens

Varies by specific receptor; includes antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and signal inhibition (Nature Reviews Drug Discovery, 2018).